We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHCT
651
Community Healthcare Trust
CHCT
$540M
| $1.55M | 0.01% |
32,698
+23,832
| +269% | +$1.17M |
|
652
Corpay
CPAY
$24.7B
| $1.53M | 0.01% |
5,974
-9,432
| -61% | -$2.61M |
|
653
New York Times
NYT
$11.9B
| $1.52M | 0.01% |
34,916
-7,503
| -18% | -$334K |
|
654
DXP Enterprises
DXPE
$2.5B
| $1.5M | 0.01% |
45,112
-81,344
| -64% | -$2.51M |
|
655
MarketAxess Holdings
MKTX
$4.2B
| $1.5M | 0.01% |
3,239
+1,715
| +113% | +$816K |
|
656
Universal Technical Institute
UTI
$2.09B
| $1.5M | 0.01% |
231,445
+4,234
| +2% | +$25K |
|
657
Dianthus Therapeutics
DNTH
$5.7B
| $1.49M | 0.01% |
9,531
+128
| +1% | +$23.5K |
|
658
Booz Allen Hamilton
BAH
$8.65B
| $1.49M | 0.01% |
+17,446
| New | +$1.47M |
|
659
E.W. Scripps
SSP
$276M
| $1.47M | 0.01% |
+72,257
| New | +$1.51M |
|
660
Manhattan Associates
MANH
$9.6B
| $1.47M | 0.01% |
10,135
-2,094
| -17% | -$279K |
|
661
Community Trust Bancorp
CTBI
$1.39B
| $1.47M | 0.01% |
36,280
| – | – |
|
662
Northeast Bank
NBN
$1.14B
| $1.45M | 0.01% |
48,426
| – | – |
|
663
Southern First Bancshares
SFST
$585M
| $1.44M | 0.01% |
28,193
+1,401
| +5% | +$72.4K |
|
664
Asbury Automotive
ABG
$4.21B
| $1.43M | 0.01% |
+8,366
| New | +$1.61M |
|
665
Five Below
FIVE
$11.4B
| $1.43M | 0.01% |
7,416
+454
| +7% | +$86.7K |
|
666
Becton Dickinson
BDX
$44.1B
| $1.43M | 0.01% |
6,037
-677
| -10% | -$162K |
|
|
FSP
667
Franklin Street Properties
FSP
$45.6M
| $1.43M | 0.01% |
271,935
+69,457
| +34% | +$373K |
|
668
American Vanguard Corp
AVD
$75.8M
| $1.43M | 0.01% |
+81,596
| New | +$1.55M |
|
|
CNCE
669
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.42M | 0.01% |
337,436
+222,504
| +194% | +$942K |
|
|
STFC
670
DELISTED
State Auto Financial Corp
STFC
| $1.4M | 0.01% |
81,946
+16,728
| +26% | +$313K |
|
671
Quad
QUAD
$445M
| $1.4M | 0.01% |
336,233
+92,715
| +38% | +$336K |
|
672
RBB Bancorp
RBB
$449M
| $1.4M | 0.01% |
57,600
+3,957
| +7% | +$88.5K |
|
673
Northwest Natural Holdings
NWN
$2.17B
| $1.39M | 0.01% |
+26,424
| New | +$1.43M |
|
|
PVLA
674
Palvella Therapeutics
PVLA
$2.03B
| $1.38M | 0.01% |
4,518
-2,242
| -33% | -$492K |
|
|
OPTN
675
DELISTED
OptiNose
OPTN
| $1.38M | 0.01% |
29,602
-1,378
| -4% | -$70.4K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.